Tezacaftor and ivacaftor combination therapy for treating cystic fibrosis with the F508del mutation [ID1303]
Discontinued
Reference number: GID-TA10277
November 2019: Tezacaftor and ivacaftor combination therapy is available on the NHS for treating cystic fibrosis.
NHS England has agreed an interim access agreement with Vertex Pharmaceuticals, which includes collecting further data through an interim data collection agreement - https://www.nice.org.uk/about/what-we-do/our-programmes/nice-guidance/nice-technology-appraisal-guidance/data-collection-agreement.